Bruker Acquires Spectral Instruments Imaging, the Performance Leader in Preclinical In-Vivo Optical Imaging Systems
06 Febrero 2024 - 3:05PM
Business Wire
Acquisition Complements Bruker’s Preclinical
Imaging Portfolio with In-Vivo Optical Imaging
Bruker Corporation (Nasdaq: BRKR) today announced that it has
acquired Spectral Instruments Imaging LLC, a leader in
preclinical in-vivo optical imaging systems. This acquisition fills
a gap in the technology and product portfolio of the Bruker BioSpin
Preclinical Imaging (PCI) division, broadening its range of
preclinical solutions for disease research.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240206814523/en/
Fast and highest sensitivity SII Lago X
in vivo imaging with capacity for 10 animals simultaneously (Photo:
Business Wire)
Established in 2009 in Tucson, Spectral Instruments Imaging
(SII) is at the forefront of technology for co-registered
bioluminescence (BLI), fluorescence (FLI), and X-ray preclinical
imaging. SII systems are engineered with advanced optics, patented
illumination, -90o C air-cooled high sensitivity cameras, absolute
calibration for quantifiable imaging, excellent flexibility and
ease of use.
The SII flagship system Lago X is designed for superior
sensitivity and high-volume in-vivo imaging research. The SII
high-efficiency AMI HTX system permits BLI, FLI and X-ray
imaging with a benchtop system. SII Aura software provides a
seamless workflow for enhanced productivity.
“Spectral Instruments Imaging systems perfectly complement the
Bruker Preclinical offering,” said Keith Copeland, the CEO of SII.
“Joining Bruker represents a significant milestone in our history,
and we are looking forward to enabling our customers to benefit
from different preclinical imaging modalities to understand
biological disease processes even more comprehensively in
vivo.”
Dr. Wulf-Ingo Jung, President of Bruker’s PCI division
commented: “We are very pleased to welcome the talented SII team.
Their advanced BLI, FLI and X-ray imaging systems complement our
portfolio to better serve the diverse needs of our preclinical
customers. We are committed to fostering strong collaborations with
our customers for advanced preclinical in vivo disease
research.”
Financial details of the transaction were not disclosed. In
2023, SII generated revenues of over $10 million and was
profitable.
About Bruker Corporation (Nasdaq: BRKR)
Bruker is enabling scientists to make breakthrough discoveries
and develop new applications that improve the quality of human
life. Bruker’s high performance scientific instruments and high
value analytical and diagnostic solutions enable scientists to
explore life and materials at molecular, cellular and microscopic
levels. In close cooperation with our customers, Bruker is enabling
innovation, improved productivity and customer success in life
science molecular and cell biology research, in applied and pharma
applications, in microscopy and nanoanalysis, as well as in
industrial applications. Bruker offers differentiated, high-value
life science and diagnostics systems and solutions in preclinical
imaging, clinical phenomics research, proteomics and multiomics,
spatial and single-cell biology, functional structural and
condensate biology, as well as in clinical microbiology and
molecular diagnostics. For more information, please visit:
www.bruker.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240206814523/en/
Investor Contact: Justin Ward Sr. Director, Investor
Relations & Corporate Development Bruker Corporation T: +1
(978) 313-5800 E: Investor.Relations@bruker.com
Media Contact: Markus Ziegler Sr. Director and Head of
Group Marketing Bruker BioSpin T: +49 172 3733531 E:
pr@bruker.com
Bruker (NASDAQ:BRKR)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Bruker (NASDAQ:BRKR)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024